Immunic AG

Address: Lochhamer Schlag 21, Lochham

Sponsor Overview

assignment

Specializations

Multiple Sclerosis Therapeutics

Immunic AG’s clinical research is centered on multiple sclerosis, with active studies in relapsing multiple sclerosis and relapsing-remitting multiple sclerosis. The programme includes evaluation of disease activity, relapse prevention, and neurological outcomes in adults with active disease.

Relapsing multiple sclerosis
Relapsing-remitting multiple sclerosis
Disease activity assessment

Clinical interest in this area includes treatment of inflammatory disease activity and control of relapse-related progression.

Progressive Multiple Sclerosis

The sponsor also studies progressive forms of multiple sclerosis, with attention to measures of neurodegeneration and structural change in the brain. This area reflects a focus on the unmet therapeutic needs of patients with worsening disability.

Progressive multiple sclerosis
Brain atrophy
Neurodegeneration

Research in this field includes clinical evaluation of outcomes linked to structural preservation and long-term neurological function.

Magnetic Resonance Imaging and Disease Monitoring

Several trials use magnetic resonance imaging to examine inflammatory and structural markers of multiple sclerosis. Imaging-based endpoints are used to characterize lesion burden, brain volume loss, and overall disease activity.

MRI-based disease assessment
Whole brain atrophy
Structural imaging biomarkers

This area supports clinical interest in objective monitoring of central nervous system disease processes.

Drug Interaction and Pharmacokinetics

Immunic AG also funds studies on the pharmacokinetics and drug-drug interaction profile of IMU-838, including interactions relevant to co-administered therapies and common concomitant medications. These studies support the therapeutic development of the compound in multiple sclerosis populations.

Pharmacokinetic profiling
Drug-drug interaction studies
Concomitant medication considerations

Research in this area includes evaluation of absorption, elimination, and compatibility with other treatments used in clinical practice.

Sponsored Trials

Trial Name	Country	Status
A Phase 1 Study to Evaluate the Pharmacokinetics and Drug-Drug Interaction Potential of IMU-838 and Oral Contraceptives in Women with Multiple Sclerosis	Belgium	Recruiting
Effect of Curcumin on the Pharmacokinetics of IMU 838 and Rosuvastatin in Subjects with Multiple Sclerosis	The Netherlands	Not Recruiting
Efficacy, Safety, and Tolerability of Vidofludimus Calcium in Progressive Multiple Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	Bulgaria Czechia Germany Poland Romania The Netherlands	Recruiting
Pharmacokinetics of IMU-838 Alone and with Gemfibrozil or Rifampicin in Healthy Subjects: A Phase 1 Study on Multiple Sclerosis	The Netherlands	Not Recruiting
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Vidofludimus Calcium on MRI-Assessed Disease Activity in Relapsing-Remitting Multiple Sclerosis	Bulgaria Germany Poland Romania	Recruiting
Phase 3 Randomized Double-Blind Study of Vidofludimus Calcium Versus Placebo in Adults with Relapsing Multiple Sclerosis	Estonia Germany Poland Romania	Not Recruiting
Phase 3 Randomized, Double‑Blind Study of IMU‑838 (vidofludimus calcium) versus Placebo in Adults with Relapsing Multiple Sclerosis	Bulgaria Germany Lithuania Poland	Not Recruiting
Randomized, Placebo‑Controlled Study of IMU‑838 on Cardiac Repolarization (QT/QTc) in Adults With Multiple Sclerosis	Belgium	Recruiting